Industry Notes / Pharma / Chapter 15 of 20 · Thesis cards
Japan mirror: thirty years of price deflation
The endgame of payer pressure can be that patients cannot get drugs
Drug Loss: the endgame risk of price cuts
About three fifths of the missing set never even started development. Emerging biotech, orphan, and pediatric drugs are especially absent.
The risk is not only company losses—it is patients missing new drugs.
How the deflation machine runs
Biennial cuts → mid-year cuts; volume clawbacks; long-listed brands stepped down to generic prices.
Same direction as China’s generics crush + innovative-drug side path, only slower historically.
The Takeda sample
Globalization worked—and nearly ¥4.9 tn of interest-bearing debt turned the firm into a repayment machine, with R&D down year on year.
Going out is survival; buying scale with leverage can kill capital efficiency.
A warning for China
Aging raises demand and squeezes payers; the two do not cancel.
Any story that “aging ⇒ pharma boom” skips the denominator.
Japan ran drug-price cuts for three decades; China built a dual-track sketch in under ten years. Takeda pushed Japan sales to about 10% and US sales to about 48%—you must get near the profit pool—while leveraged M&A can lock R&D freedom.
Source：日本厚生劳动省（MHLW）薬価改定与中医协文件；Drug Loss 统计公开口径；武田制药 FY2025 披露
Research notes, not investment advice.